@article{d4d39ddcf11941e289bbada4705e74bd,
title = "Phase I study of single-agent CC-292, a highly selective bruton{\textquoteright}s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia",
keywords = "BTK inhibitors, CC-292, Chronic lymphocytic leukemia, Refractory, Relapsed, Single-agent, Small lymphocytic lymphoma",
author = "Brown, \{Jennifer R.\} and Harb, \{Wael A.\} and Hill, \{Brian T.\} and Janice Gabrilove and Sharman, \{Jeff P.\} and Schreeder, \{Marshall T.\} and Barr, \{Paul M.\} and Foran, \{James M.\} and Miller, \{Thomas P.\} and Burger, \{Jan A.\} and Kelly, \{Kevin R.\} and Daruka Mahadevan and Shuo Ma and Yan Li and Pierce, \{Daniel W.\} and Evelyn Barnett and Jeffrey Marine and Monika Miranda and Ada Azaryan and Xujie Yu and Pilar Nava-Parada and Jay Mei and Kipps, \{Thomas J.\}",
year = "2016",
doi = "10.3324/haematol.2015.140806",
language = "English (US)",
volume = "101",
pages = "e295--e298",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",
}